N/A N=30 Randomized Quadruple-blind Treatment

Effect of Whole-body Photobiomodulation on Muscular Performance Enhancement.

Sports Performance · Injury Prevention · Muscle Damage · Musculoskeletal Pain

Bottom Line

View on ClinicalTrials.gov: NCT05989815 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2025

Primary outcome: Primary: Measurement of Blood Levels of Creatine Phosphokinase (CK) — 287.8; 249.2; 289.2 U/L

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Muscle damage protocol training (Other); Photobiomodulation therapy (PBMT) (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: Male
Sponsor: Universidade Federal de Sao Carlos
Primary completion: Nov 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Measurement of Blood Levels of Creatine Phosphokinase (CK)	287.8; 249.2; 289.2	—
SECONDARY Squat Jump (SJ) Height	37.38; 38.91; 38.56	—
SECONDARY Muscle Performance Tests - Dynamometry	59.19; 53.45; 55.58	—
SECONDARY Delayed Onset Muscle Soreness (DOMS)	3.00; 3.80; 5.70	—
SECONDARY Countermovement Jump (CMJ) Height	39.36; 41.56; 40.55	—

Summary

Introduction: Photobiomodulation therapy (PBMT) is based on the emission of light ranging from red to near-infrared spectra by different devices based on diode lasers or light-emitting diodes. These devices emitting different wavelengths can increase mitochondrial activity and energy synthesis (ATP - adenosine triphosphate) that in turn can help to prevent muscle damage, decrease muscle fatigue and enhance muscle performance. Thus, PBMT can be a promising therapeutic resource in the sports field. Objectives: The aim of this study is to verify the effect of PBMT on the muscle performance and prevention of muscle damage and delayed onset muscle soreness (DOMS) in professional soccer players submitted to a muscle damage protocol. Methodology: The present study is a randomized sham-controlled clinical trial following the CONSORT guidelines.

Eligibility Criteria

Inclusion Criteria

Male individuals aged between 18 and 35 years, professional soccer players who engage in training at least 5 times a week, will be selected.

Data collection will be conducted at the Desportivo Brasil Football Club, located in Porto Feliz, São Paulo. The sample will consist of team members, with a total of 30 athletes established to compose the sample. All data collection will take place in the same location.

Exclusion Criteria

Individuals with any impediment to physical activity or those presenting dysfunctions that may impair the neuromuscular system will be excluded.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05989815). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.